General characteristics at inclusion
| Characteristic | Rituximab infusions | |
| Individually tailored (N=81) | Fixed-schedule (N=81) | |
| Age — yr | 62±14 | 59±13 |
| Female sex — no. (%) | 31 (38.3) | 37 (45.7) |
| Vasculitis type — no. (%) | ||
| GPA | 56 (69.1) | 61 (75.3) |
| MPA | 25 (30.9) | 20 (24.7) |
| Disease status — no. (%) | ||
| Newly diagnosed | 53 (65.4) | 51 (63.0) |
| Relapsing | 28 (34.6) | 30 (37.0) |
| Induction treatment of last disease flare — no. (%) | ||
| Cyclophosphamide | 52 (64.2) | 49 (60.5) |
| RTX | 28 (34.6) | 32 (39.5) |
| Methotrexate | 1 (1.2) | 0 (0.0) |
| Prednisone dose (mg); median (IQR) | 10 (10–15) | 12 (10–17.3) |
| Organ involvement at last flare — no. (%) | ||
| Ear, nose and throat | 46 (56.8) | 39 (48.1) |
| Pulmonary | 50 (61.7) | 44 (54.3) |
| Renal | 60 (74.1) | 56 (69.1) |
| GFR — ml/min/1.73 m2 at inclusion | 55.6±27.3 | 58.9±27.0 |
| ANCA-positive at diagnosis — no. (%)* | 74/77 (96.1) | 72/79 (91.1) |
| Indirect immunofluorescence | 68/77 (88.3) | 6579 (82.3) |
| ELISA | 64/77 (83.1) | 61/79 (77.2) |
| Anti-PR3 | 38/77 (49.4) | 38/79 (48.1) |
| Anti-MPO | 26/77 (33.8) | 24/79 (30.4) |
| ANCA-positive at inclusion — no. (%)† | 58/80 (72.5) | 45/80 (56.3) |
| Indirect immunofluorescence | 54/80 (67.5) | 40/80 (50) |
| ELISA | 43 (53.7) | 28 (35) |
| Anti-PR3 | 21 (26.2) | 18 (22.5) |
| Anti-MPO | 23 (28.7) | 10 (12.5) |
Plus–minus values are means ±SD. GPA denotes granulomatosis with polyangiitis, MPA microscopic polyangiitis, ANCA antineutrophil cytoplasm antibodies, PR3 proteinase-3, MPO myeloperoxidase and GFR glomerular filtration rate.
*Data were missing for 4 individually tailored-infusion and 2 fixed-schedule patients.
†Data were missing for 1 patient in each group.